Shots: The P-III ANDROMEDA (AMY3001) study involves assessing of Daratumumab (SC) + cyclophosphamide + bortezomib + dexamethasone (CyBorD) vs CyBorD as monothx. in 388 patients newly diagnosed with AL amyloidosis, conducted by Janssen The P-III ANDROMEDA study resulted in meeting its 1EPs of the percentage of patients with hematologic complete response (53.3% vs 18.1%), the […]Read More
